News & Articles

Detecting lung cancer early with advanced flow cytometry

Diagnostics

CyPath® Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk.

Therapeutics

Through our subsidiary, OncoSelect® Therapeutics, we are advancing our discoveries to create broad-spectrum cancer therapeutics.

Our Most Recent News, Events, Press Releases

Latest Information

Latest Updates

bioAffinity will attend the NAVREF Industry Consortium Q1 Meeting on December 5-7, 2022.

December 1, 2022 bioAffinity will attend the NAVREF Industry Consortium Q1 Meeting on December 5-7, 2022 in Miami Florida. About The IPC Meeting for FY23 Q1 This day-and-a-half meeting is designed to be an opportunity to launch our efforts in 2023.  In addition to revisiting previous business, the agenda will also include: Guest speaker benefiting from partnered research with VA VA speakers from the Artificial Intelligence team Getting to the finish line: the realization of the Data Analyst role Finalization of the IPC Charter and shaping the dynamics of the IPC DCT: The Hub and Spoke Approach Developing the communication network and infrastructure for future studies...
Read More
Full Catalog of Prior Articles, News, Events, and Press Releases

Prior Articles

News & Articles

Precision Pathology Services

Learn More about CyPath® Lung

The CyPath® Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT).

CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.

The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.

Physician Portal

Patient Portal

How to Order

CyPath® FAQ